Evaluation of the Impact of the Clinical Pharmacist in the Initiation and Follow-up of Oral Therapies in Oncology.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Observance
研究概览
简要总结
The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the hospital and the patient's home pharmacy, so that the patient can continue to receive care at home. It is also essential that the hospital pharmacy and the patient's local pharmacy work together within a reasonable timeframe. This will help improve patient care and treatment follow-up, detect any undesirable effects and optimize their management..
The aim of this prospective interventional study is to measure the benefits of pharmaceutical monitoring in healthcare institutions at the initiation of oral therapy on patient compliance, side-effect management and adherence, in comparison with patients without this monitoring.
The primary endpoint is compliance with the Girerd questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient suffering from an oncological pathology (excluding hematological malignancies)
- •Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments).
- •Patient who has not yet started treatment or who has started treatment less than 30 days
- •Patient with continuation of oral therapy dispensed in pharmacies
排除标准
- •Patients suffering from hematological malignancies
- •Patient living in an institution or hospital
- •Patient under treatment for more than 30 days
- •Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment)
- •Patient whose treatment after initiation is not dispensed in a pharmacy
研究组 & 干预措施
specialized pharmaceutical consultation
干预措施: Pharmaceutical consultation (Procedure)
specialized pharmaceutical consultation and follow-up in hospitals and community pharmacies
干预措施: Pharmaceutical consultation and follow-up (Procedure)
结局指标
主要结局
Observance
时间窗: 3 months and 6 months after treatment initiation
The measurement of the primary endpoint is based on the use of a validated scale for assessing medication compliance: the Girerd scale. This is a 6-question questionnaire with a binary yes/no response. The score ranges from 0 to 6, with a "yes" worth 1 point.
次要结局
未报告次要终点